Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis

Kidney International

Volumn 70, Issue 5, 2006, Pages 938-947

  Abdulahad, W H ^a   Van Der Geld, Y M ^a   Stegeman, C A ^a   Kallenberg, C G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Central memory T cells; Effector memory T cells; T cells; Wegener's granulomatosis

Indexed keywords

CD4 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; INTERLEUKIN 18 RECEPTOR ALPHA; INTERLEUKIN RECEPTOR; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CELL ISOLATION; CONTROLLED STUDY; CORRELATION ANALYSIS; EFFECTOR CELL; FEMALE; HOMEOSTASIS; HUMAN; IMMUNOPATHOGENESIS; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REMISSION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; WEGENER GRANULOMATOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD45; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; RECEPTORS, CHEMOKINE; REMISSION, SPONTANEOUS; T-LYMPHOCYTE SUBSETS; TH1 CELLS; TH2 CELLS; WEGENER GRANULOMATOSIS;

EID: 33747858975     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001670     Document Type: Article

References (52)

1. Fauci AS, Haynes BF, Katz P et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76-85.
2. Hoffman GS, Kerr GS, Leavitt RY et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-498.
3. Gephardt GN, Ahmad M, Tubbs RR. Pulmonary vasculitis (Wegener's granulomatosis). Immunohistochemical study of T and B cell markers. Am J Med 1983; 74: 700-704.
4. ten Berge IJ, Wilmink JM, Meyer CJ et al. Clinical and immunological follow-up of patients with severe renal disease in Wegener's granulomatosis. Am J Nephrol 1985; 5: 21-29.
5. Bolton WK, Innes Jr DJ, Sturgill BC et al. T-cells and macrophages in rapidly progressive glomerulonephritis: clinicopathologic correlations. Kidney Int 1987; 32: 869-876.
6. Savage CO, Harper L, Holland M. New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis. Curr Opin Rheumatol 2002; 14: 15-22.
7. Brouwer E, Cohen Tervaert J, Weening J et al. Immunohistology of renal biopsies in Wegener's granulomatosis (WG): clues to its pathogenesis. Kidney Int 1991; 39: 1055.
8. Lockwood CM, Thiru S, Stewart S et al. Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. Q J Med 1996; 89: 903-912.
9. Hagen EC, de Keizer RJ, Andrassy K et al. Compassionate treatment of Wegener's granulomatosis with rabbit anti-thymocyte globulin. Clin Nephrol 1995; 43: 351-359.
10. + T-cell subsets in Wegener's granulomatosis. Rheumatol Int 1995; 14: 213-219.
11. Schmitt WH, Heesen C, Csernok E et al. Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. Arthritis Rheum 1992; 35: 1088-1096.
12. Wang G, Hansen H, Tatsis E et al. High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis. Am J Med 1997; 102: 517-523.
13. D'Cruz D, Direskeneli H, Khamashta M et al. Lymphocyte activation markers and von Willebrand factor antigen in Wegener's granulomatosis: potential markers for disease activity. J Rheumatol 1999; 26: 103-109.
14. Popa ER, Stegeman CA, Bos NA et al. Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 1999; 103: 885-894.
15. Giscombe R, Nityanand S, Lewin N et al. Expanded T cell populations in patients with Wegener's granulomatosis: characteristics and correlates with disease activity. J Clin Immunol 1998; 18: 404-413.
16. Balding CE, Howie AJ, Drake-Lee AB et al. Th2 dominance in nasal mucosa in patients with Wegener's granulomatosis. Clin Exp Immunol 2001; 125: 332-339.
17. Coulomb-L'Hermine A, Capron F, Zou W et al. Expression of the chemokine RANTES in pulmonary Wegener's granulomatosis. Hum Pathol 2001; 32: 320-326.
18. Sallusto F, Lenig D, Forster R et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712.
19. Hamann D, Baars PA, Rep MH et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 1997; 186: 1407-1418.
20. Stegeman CA, Tervaert JW, Sluiter WJ et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120: 12-17.
21. Lamprecht P, Erdmann A, Mueller A et al. Heterogeneity of CD4 and CD8+ memory T cells in localized and generalized Wegener's granulomatosis. Arthritis Res Ther 2003; 5: R25-R31.
22. Chan WL, Pejnovic N, Lee CA et al. Human IL-18 receptor and ST2L are stable and selective markers for the respective type 1 and type 2 circulating lymphocytes. J Immunol 2001; 167: 1238-1244.
23. + regulatory T cells. J Exp Med 2004; 199: 303-313.
24. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061.
25. + regulatory T cells. Int Immunol 2004; 16: 1643-1656.
26. Kim CH, Rott L, Kunkel EJ et al. Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest 2001; 108: 1331-1339.
27. + lymphocytes in physically active adults. Eur J Immunol 1993; 23: 2704-2706.
28. Iezzi G, Scheidegger D, Lanzavecchia A. Migration and function of antigen-primed nonpolarized T lymphocytes in vivo. J Exp Med 2001; 193: 987-993.
29. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004; 22: 745-763.
30. Zaph C, Uzonna J, Beverley SM et al. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat Med 2004; 10: 1104-1110.
31. Wulff H, Calabresi PA, Allie R et al. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest 2003; 111: 1703-1713.
32. Beeton C, Wulff H, Barbaria J et al. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci USA 2001; 98: 13942-13947.
33. Benveniste O, Herson S, Salomon B et al. Long-term persistence of clonally expanded T cells in patients with polymyositis. Ann Neurol 2004; 56: 867-872.
34. Hong K, Berg EL, Ehrhardt RO. Persistence of pathogenic CD4+ Th1-like cells in vivo in the absence of IL-12 but in the presence of autoantigen. J Immunol 2001; 166: 4765-4772.
35. + regulatory T cells. J Exp Med 2004; 199: 303-313.
36. Lamprecht P, Moosig F, Csernok E et al. CD28 negative T cells are enriched in granulomatous lesions of the respiratory tract in Wegener's granulomatosis. Thorax 2001; 56: 751-757.
37. Caruso AM, Serbina N, Klein E et al. Mice deficient in CD4T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J Immunol 1999; 162: 5407-5416.
38. Di Perri G, Cazzadori A, Vento S et al. Comparative histopathological study of pulmonary tuberculosis in human immunodeficiency virus-infected and non-infected patients. Tuberc Lung Dis 1996; 77: 244-249.
39. + memory T cells homing to the joints in juvenile idiopathic arthritis. Arthritis Res Ther 2005; 7: R256-R267.
40. Sakatsume M, Xie Y, Ueno M et al. Human glomerulonephritis accompanied by active cellular infiltrates shows effector T cells in urine. J Am Soc Nephrol 2001; 12: 2636-2644.
41. Friedrich M, Krammig S, Henze M et al. Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res 2000; 292: 519-521.
42. Csernok E, Trabandt A, Muller A et al. Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 1999; 42: 742-750.
43. + T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol 1998; 160: 3602-3609.
44. Komocsi A, Lamprecht P, Csernok E et al. Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis. Am J Pathol 2002; 160: 1717-1724.
45. - T-cells and in granulomatous lesions between localized and generalized Wegener's granulomatosis. Clin Immunol 2003; 108: 1-7.
46. Popa ER, Franssen CF, Limburg PC et al. In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3- and antimyeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase. Arthritis Rheum 2002; 46: 1894-1904.
47. + T lymphocytes in response to Staphylococcus aureus in patients with Wegener's granulomatosis. Scand J Immunol 1999; 49: 585-594.
48. Leavitt RY, Fauci AS, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 1101-1107.
49. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192.
50. Luqmani RA, Bacon PA, Moots RJ et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994; 87: 671-678.
51. Fink PC, Romer M, Haeckel R et al. Measurement of proteins with the Behring Nephelometer. A multicentre evaluation. J Clin Chem Clin Biochem 1989; 27: 261-276.
52. Tervaert JW, Mulder L, Stegeman C et al. Occurrence of autoantibodies to human leucocyte elastase in Wegener's granulomatosis and other inflammatory disorders. Ann Rheum Dis 1993; 52: 115-120.